Our science
Science & platform
A discovery platform designed around human tissue, not around convenience.
01
Human-first target discovery
We profile immune cell states directly from patient biopsies at single-cell resolution, then triangulate candidate targets against human genetic association data before any medicinal chemistry begins.
02
Selective modulation, not blunt suppression
Our chemistry is optimised for tissue-restricted exposure, aiming to correct pathogenic signalling in the affected compartment while preserving systemic immune competence.
03
Translational rigour
Every clinical program carries a pre-specified biomarker strategy, so that a negative study still yields an interpretable answer about the mechanism.
